Safety and efficacy of intravitreal triamcinolone acetonide for uveitis macular edema

Intravitreal Triamcinolone Acetonide as Adjunctive Treatment with Systemic Therapy for Uveitic Macular Edema

“…Use of additional local treatment may allow control of the CME and reduce the need to elevate systemic therapy usually required to achieve this. Several studies, mostly consisting of small case series, have been published on the efficacy and safety of single and multiple intravitreal triamcinolone acetonide (IVTA) injections in uveitic CME (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). The aim of this study was to evaluate the effect of a single 4 mg/0.1 mL IVTA injection in patients with otherwise quiescent uveitis controlled on low-dose corticosteroids ± a second-line agent for recurrent or persistent CME.…”

“…In 2 other eyes that had an epiretinal membrane, IVTA treatment was not effective and the CME did It is well-known that IVTA injection can induce IOP elevation. Several studies (5,6,9,11,16,17) have reported on the short-term safety of 4 mg/0.1 mL IVTA injection and showed that elevated IOP ranges from 30% to 83%; the IOP elevation was transient and well-controlled in most patients with topical IOP-lowering medications. Our study results were similar: 49% of the eyes had an IOP rise of >6 mmHg, and those given additional therapy to lower IOP all responded well.…”

“…Intravitreal triamcinolone acetonide injection is also known to induce or increase posterior subcapsular cataract. Several studies (5,8,9,11,16) reported on cataract progression in 0%-83% of patients. Our study showed that posterior subcapsular cataract developed or increased in 17% of the eyes by 6 months.…”